Business
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025
Reports Net Revenues of $170.5 Million for the Three Months Ended March 31, 2025 RANCHO CUCAMONGA, CA / ACCESS Newswire / May 7, 2025 / Amphastar
About this update from Amphastar Pharmaceuticals, Inc.
[{"type":"text","content":"Reports Net Revenues of $170.5 Million for the Three Months Ended March 31, 2025 RANCHO CUCAMONGA, CA / ACCESS Newswire / May 7, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) (\"Amphastar\" or the \"Company\") today reported results for the three months ended March 31, 2025.First Quarter HighlightsNet revenues of $170.5 million for the first quarterGAAP net income of $25.3 million, or $0.51 per share, for the first quarterAdjusted non-GAAP net income of $36.9 million, or $0.74 per share, for the first quarterDr. Jack Zhang, Amphastar's President and Chief Executive Officer, commented: \"We are confident in the potential of our portfolio, particularly with the growth of BAQSIMI® and Primatene MIST®, and the promising pipeline of biosimilars and proprietary products. The FDA's acceptance of our AMP-004 insulin biosimilar application in April marks a significant milestone towards expanding our biosimilar offerings. We are strategically managing our resources to ensure efficient operations and remain firmly committed to achieving our long-term goals of delivering sustainable growth and maximizing shareholder value.\" Three Months Ended March 31, 2025 2024 (in thousands, except per share data) Net revenues $170,528 $171,836 GAAP net income $25,285 $43,177 Adjusted non-GAAP net income* $36,871 $55,296 GAAP diluted EPS $0.51 $0.81 Adjusted non-GAAP diluted EPS* $0.74 $1.04 ______________________________________* Adjusted non-GAAP net income and adjusted non-GAAP diluted EPS are non-GAAP financial measures. Please see the discussion in the section entitled \"Non-GAAP Financial Measures\" and the reconciliation of GAAP to non-GAAP financial measures in Table III of this press release.First Quarter Results Three Months Ended March 31, Change 2025 2024 Dollars % (in thousands) Product revenues, net: BAQSIMI® $38,355 $13,843 $24,512 177%Primatene MIST® 29,051 24,166 4,885 20%Glucagon 20,843 28,535 (7,692) (27)%Epinephrine 18,587 26,110 (7,523) (29)%Lidocaine 13,644 12,773 871 7%Other products 50,048 52,202 (2,154) (4)%Total product revenues, net $170,528 $157,629 $12,899 8%Other revenues - 14,207 (14,207) (100)%Total net revenues $170,528 $171,836 $(1,308) (1)%Changes in net revenues as compared to the first quarter of the prior year were primarily driven by:BAQSIMI® sales increased primarily due to an increase in unit volume, as we ...